Retatrutide, also known by its research identifier LY3437943, is an investigational triple agonist peptide developed by Eli Lilly and Company. It targets three key metabolic hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This combination is designed to enhance weight loss and improve metabolic health beyond what existing single or dual agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) can achieve. The drug is currently in Phase 3 clinical trials for multiple indications, including obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH, now referred to as metabolic dysfunction-associated steatohepatitis or MASH), and knee osteoarthritis. The prediction market question asks whether the FDA will grant any form of approval for retatrutide before the end of the current year, a scenario that appears unlikely given the typical timeline for Phase 3 trials and regulatory review. Interest in retatrutide stems from its impressive early clinical data. In a Phase 2 trial published in the New England Journal of Medicine in 2023, participants with obesity or overweight without diabetes lost up to 24.2% of their body weight after 48 weeks on the highest dose (12 mg), surpassing results seen with existing GLP-1-based therapies. This level of weight loss approaches that of bariatric surgery, making retatrutide a potential blockbuster. Eli Lilly has initiated a broad Phase 3 program, including trials like TRIUMPH, which covers obesity, type 2 diabetes, and other conditions. The company has also stated that it expects to complete regulatory submissions for retatrutide in 2025, with a possible approval in 2026. Therefore, an FDA approval this year is highly improbable, and the market likely reflects this low probability. The broader context includes the explosive growth of the GLP-1 drug market, projected to reach $100 billion annually by 2030. Eli Lilly and Novo Nordisk are the dominant players, with Lilly's tirzepatide already approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Retatrutide represents the next frontier, with the potential to offer even greater efficacy and possibly improve outcomes in conditions like MASH and osteoarthritis, where metabolic dysfunction plays a role. The FDA's willingness to approve such drugs has been demonstrated, but the agency requires substantial evidence of safety and efficacy from adequate and well-controlled trials. Given that Phase 3 trials are still ongoing, an approval this year would require an unprecedented acceleration, such as a breakthrough therapy designation and rolling review, but even then, the data would not be available in time. For market participants, the question hinges on the FDA's regulatory pathways and Eli Lilly's submission timeline. As of now, no New Drug Application (NDA) or Biologics License Application (BLA) has been submitted for retatrutide, and the company has not announced any plans to do so before the end of the year. The FDA does have mechanisms like accelerated approval for serious conditions, but obesity and diabetes are not typically eligible for that pathway unless there is an unmet need. Moreover, the FDA requires a six-month priority review or ten-month standard review once an application is submitted, making it logistically impossible to receive approval by December 31 if the submission is not made until later this year. Thus, the market is likely trading at a very low probability, and the educational value of this topic lies in understanding the drug, the clinical trial process, and the regulatory environment.

Historical Context

The development of incretin-based therapies began with the discovery of GLP-1 in the 1980s, leading to the first GLP-1 receptor agonist, exenatide, approved in 2005 for type 2 diabetes. Since then, the field has progressed rapidly, with semaglutide (approved as Ozempic in 2017 and Wegovy for obesity in 2021) becoming a blockbuster. Tirzepatide, a dual GIP and GLP-1 receptor agonist, was approved for type 2 diabetes in 2022 and for obesity in 2023, showing superior weight loss to semaglutide in head-to-head trials. Retatrutide adds a third agonist, glucagon, which may further enhance energy expenditure and fat metabolism. The regulatory precedent for obesity drugs has evolved. After fen-phen was withdrawn in 1997 due to heart valve issues, the FDA became cautious, but the approval of semaglutide and tirzepatide has renewed confidence. The FDA has also shown flexibility with accelerated approval for certain drugs, but it has not applied that to obesity. The typical timeline from Phase 3 completion to FDA approval is 1-2 years. For example, tirzepatide's Phase 3 trials ended in 2021, and it received approval for diabetes in May 2022, about 10 months after submission. For obesity, the submission was made in 2022, with approval in November 2023. This suggests that even if retatrutide's Phase 3 trials were completed now, approval would not occur until at least late 2025 or 2026. In the history of FDA approvals, there have been rare instances of rapid approvals, such as for certain cancer drugs using accelerated pathways, but these are exceptions. For metabolic drugs, the FDA requires large cardiovascular outcomes trials to assess safety, which often take years. Eli Lilly has initiated a cardiovascular outcomes trial for retatrutide, which will likely not be completed until 2027 or later. Therefore, the historical context strongly indicates that an approval this year is not feasible.